Pembrolizumab/chemotherapy regimens are strongly recommended as first-line regimens for patients with metastatic non-squamous NSCLC, no contraindications to immunotherapy, and negative results of EGFR, ALK, ROS1, or BRAF genetic alterations, regardless of PD-L1 expression levels. Here, EGFR is linked to non-small cell lung carcinoma.